The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Outcomes of Localized Prostate Cancer Following Conservative Management
Open accessAbstract
CONTEXT: Most newly diagnosed prostate cancers are clinically localized, and major treatment options include surgery, radiation, or conservative management. Although conservative management can be a reasonable choice, there is little contemporary prostate-specific antigen (PSA)-era data on outcomes with this approach. OBJECTIVE: To evaluate the outcomes of clinically localized prostate cancer managed without initial attempted curative therapy in the PSA era. DESIGN, SETTING, AND PARTICIPANTS: A population-based cohort study of men aged 65 years or older when they were diagnosed (1992-2002) with stage T1 or T2 prostate cancer and whose cases were managed without surgery or radiation for 6 months after diagnosis. Living in areas covered by the Surveillance, Epidemiology, and End Results (SEER) program, the men were followed up for a median of 8.3 years (through December 31, 2007). Competing risk analyses were performed to assess outcomes. MAIN OUTCOME MEASURES: Ten-year overall survival, cancer-specific survival, and major cancer related interventions. RESULTS: Among men who were a median age of 78 years at cancer diagnosis, 10-year prostate cancer-specific mortality was 8.3% (95% confidence interval [CI], 4.2%-12.8%) for men with well-differentiated tumors; 9.1% (95% CI, 8.3%-10.1%) for those with moderately differentiated tumors, and 25.6% (95% CI, 23.7%-28.3%) for those with poorly differentiated tumors. The corresponding 10-year risks of dying of competing causes were 59.8% (95% CI, 53.2%-67.8%), 57.2% (95% CI, 52.6%-63.9%), and 56.5% (95% CI, 53.6%-58.8%), respectively. Ten-year disease-specific mortality for men aged 66 to 74 years diagnosed with moderately differentiated disease was 60% to 74% lower than earlier studies: 6% (95% CI, 4%-8%) in the contemporary PSA era (1992-2002) compared with results of previous studies (15%-23%) in earlier eras (1949-1992). Improved survival was also observed in poorly differentiated disease. The use of chemotherapy (1.6%) or major interventions for spinal cord compression (0.9%) was uncommon. CONCLUSIONS: Results following conservative management of clinically localized prostate cancer diagnosed from 1992 through 2002 are better than outcomes among patients diagnosed in the 1970s and 1980s. This may be due, in part, to additional lead time, overdiagnosis related to PSA testing, grade migration, or advances in medical care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Introduction to the Bootstrap
Efron, B., & Tibshirani, R. J. (1994) · doi:10.1201/9780429246593 · Cited by 40,500
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
An Introduction to the Bootstrap.
Buckland, S. T., Efron, B., & Tibshirani, R. J. (1994) · Biometrics · doi:10.2307/2532810 · Cited by 3,103
Tutorial in biostatistics: competing risks and multi‐state models
Putter, H., Fiocco, M., & Geskus, R. B. (2007) · Statistics in Medicine · doi:10.1002/sim.2712 · Cited by 2,440
Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer
Bill-Axelson, A., Holmberg, L., Ruutu, M., Garmo, H., Stark, J. R., Busch, C., Nordling, S., Häggman, M., Andersson, S.-O., Bratell, S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011967 · Cited by 1,900
Development of a comorbidity index using physician claims data
Klabunde, C. N., Potosky, A. L., Legler, J. M., & Warren, J. L. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00256-0 · Cited by 1,845
Warren, J. L., Klabunde, C. N., Schrag, D., Bach, P. B., & Riley, G. F. (2002) · PubMed · doi:10.1097/01.mlr.0000020942.47004.03 · Cited by 1,714
Risk of Fracture after Androgen Deprivation for Prostate Cancer
Shahinian, V. B., Kuo, Y.-F., Freeman, J. L., & Goodwin, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041943 · Cited by 1,375
20-Year Outcomes Following Conservative Management of Clinically Localized Prostate Cancer
Albertsen, P. C. (2005) · JAMA · doi:10.1001/jama.293.17.2095 · Cited by 1,187
Draisma, G., Boer, R., Otto, S. J., van der Cruijsen, I. W., Damhuis, R. A. M., Schroder, F. H., & de Koning, H. J. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.12.868 · Cited by 1,071
Results of Conservative Management of Clinically Localized Prostate Cancer
Chodak, G. W., Thisted, R. A., Gerber, G. S., Johansson, J.-E., Adolfsson, J., Jones, G. W., Chisholm, G. D., Moskovitz, B., Livne, P. M., & Warner, J. (1994) · New England Journal of Medicine · doi:10.1056/nejm199401273300403 · Cited by 928
Natural History of Early, Localized Prostate Cancer
Johansson, J.-E. (2004) · JAMA · doi:10.1001/jama.291.22.2713 · Cited by 703
Wilt, T. J., MacDonald, R., Rutks, I., Shamliyan, T. A., Taylor, B. C., & Kane, R. L. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-6-200803180-00209 · Cited by 597
High 10-Year Survival Rate in Patients With Early, Untreated Prostatic Cancer
Johansson, J.-E. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03480160049033 · Cited by 467
Contemporary Trends in Low Risk Prostate Cancer: Risk Assessment and Treatment
Cooperberg, M. R., Broering, J. M., Kantoff, P. W., & Carroll, P. R. (2007) · Journal of Urology · doi:10.1016/j.juro.2007.03.135 · Cited by 442
Population-based study of long-term survival in patients with clinically localised prostate cancer
Lu-Yao, G. L., & Yao, S.-L. (1997) · The Lancet · doi:10.1016/s0140-6736(96)09380-4 · Cited by 416
Self-citationUtility of the SEER-Medicare Data to Identify Chemotherapy Use
Warren, J. L., Harlan, L. C., Fahey, A., Virnig, B. A., Freeman, J. L., Klabunde, C. N., Cooper, G. S., & Knopf, K. B. (2002) · Medical Care · doi:10.1097/00005650-200208001-00008 · Cited by 404
Prostate Cancer and the Will Rogers Phenomenon
Albertsen, P. C., Hanley, J. A., Barrows, G. H., Penson, D. F., Kowalczyk, P. D. H., Sanders, M. M., & Fine, J. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji248 · Cited by 382
Hazard Rate Estimation under Random Censoring with Varying Kernels and Bandwidths
Muller, H.-G., & Wang, J.-L. (1994) · Biometrics · doi:10.2307/2533197 · Cited by 340
COOPERBERG, M. R., BROERING, J. M., LITWIN, M. S., LUBECK, D. P., MEHTA, S. S., HENNING, J. M., CARROLL, P. R., & the CaPSURE INVESTIGATORS (2004) · Journal of Urology · doi:10.1097/01.ju.0000107247.81471.06 · Cited by 340
National Practice Patterns and Time Trends in Androgen Ablation for Localized Prostate Cancer
Cooperberg, M. R., Grossfeld, G. D., Lubeck, D. P., & Carroll, P. R. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.13.981 · Cited by 329
Walsh, P. C., DeWeese, T. L., & Eisenberger, M. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmcp0706784 · Cited by 321
Studying Radiation Therapy Using SEER-Medicare-Linked Data
Virnig, B. A., Warren, J. L., Cooper, G. S., Klabunde, C. N., Schussler, N., & Freeman, J. (2002) · Medical Care · doi:10.1097/00005650-200208001-00007 · Cited by 286
Active surveillance for early‐stage prostate cancer: Review of the current literature
Dall'Era, M. A., Cooperberg, M. R., Chan, J. M., Davies, B. J., Albertsen, P. C., Klotz, L. H., Warlick, C. A., Holmberg, L., Bailey, D. E., Wallace, M. E., et al. (2008) · Cancer · doi:10.1002/cncr.23373 · Cited by 273
Delayed Versus Immediate Surgical Intervention and Prostate Cancer Outcome
Warlick, C., Trock, B. J., Landis, P., Epstein, J. I., & Carter, H. B. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj072 · Cited by 219
Wilt, T. J., Brawer, M. K., Barry, M. J., Jones, K. M., Kwon, Y., Gingrich, J. R., Aronson, W. J., Nsouli, I., Iyer, P., Cartagena, R., et al. (2009) · Contemporary Clinical Trials · doi:10.1016/j.cct.2008.08.002 · Cited by 170
Determining Cause of Death in Prostate Cancer: Are Death Certificates Valid?
Penson, D. F., Albertsen, P. C., Nelson, P. S., Barry, M., & Stanford, J. L. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.23.1822 · Cited by 129
Kawakami, J., Cowan, J. E., Elkin, E. P., Latini, D. M., DuChane, J., & Carroll, P. R. (2006) · Cancer · doi:10.1002/cncr.21799 · Cited by 107
Albertsen, P. C., WALTERS, S., & Hanley, J. A. (2000) · The Journal of Urology · doi:10.1016/s0022-5347(05)67915-3 · Cited by 104
Kattan, M. W., Cuzick, J. M., Fisher, G., Berney, D. M., Oliver, R. T. D., Foster, C. S., Møller, H., Reuter, V., Fearn, P., Eastham, J. A., et al. (2007) · Cancer · doi:10.1002/cncr.23106 · Cited by 75
Active Surveillance for Favorable Risk Prostate Cancer: What Are the Results, and How Safe Is It?
Klotz, L. H. (2008) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2007.09.001 · Cited by 30
p53 gene mutations and 17p allelic deletions in hepatocellular carcinoma from Japan
Nose, H., Imazeki, F., Ohto, M., & Omata, M. (1993) · Cancer · doi:10.1002/1097-0142(19930715)72:2
Cited by
Cancer treatment and survivorship statistics, 2016
Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21349 · Cited by 6,066
Cancer treatment and survivorship statistics, 2019
Miller, K. D., Nogueira, L., Mariotto, A. B., Rowland, J. H., Yabroff, K. R., Alfano, C. M., Jemal, A., Kramer, J. L., & Siegel, R. L. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21565 · Cited by 4,226
Cancer treatment and survivorship statistics, 2022
Miller, K. D., Nogueira, L., Devasia, T., Mariotto, A. B., Yabroff, K. R., Jemal, A., Kramer, J., & Siegel, R. L. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21731 · Cited by 3,597
Cancer treatment and survivorship statistics, 2012
Siegel, R., DeSantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., Cooper, D., Gansler, T., Lerro, C., Fedewa, S., et al. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21149 · Cited by 2,928
Cancer treatment and survivorship statistics, 2014
DeSantis, C. E., Lin, C. C., Mariotto, A. B., Siegel, R. L., Stein, K. D., Kramer, J. L., Alteri, R., Robbins, A. S., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21235 · Cited by 2,779
Metadata
- Authors
- Lu-Yao, G. L.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2009-09-16
- Volume
- 302
- Issue
- 11
- Pages
- 1202
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2125837480
- Cited by
- 430
- References
- 32
- FWCI
- 40.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.